Am J Trop Med HygAm. J. Trop. Med. HygtpmdThe American Journal of Tropical Medicine and Hygiene0002-96371476-1645The American Society of Tropical Medicine and Hygiene24106189379509210.4269/ajtmh.13-0201AJTMH and PAHO: Commemorating the 3rd Anniversary of the Cholera Outbreak in Haiti: Invited PapersModeling the Effect of Water, Sanitation, and Hygiene and Oral Cholera Vaccine Implementation in HaitiFUNG, FITTER AND OTHERSMODELING EFFECTS AND ORAL CHOLERA VACCINE IMPLEMENTATION IN HAITIChun-Hai FungIsaacFitterDavid L.BorseRebekah H.MeltzerMartin I.TapperoJordan W.*National Center for Emerging and Zoonotic Infectious Diseases, and Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia*Address correspondence to Jordan W. Tappero, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop D69, Atlanta, GA 30333. E-mail: jwt0@cdc.gov†These authors contributed equally to this article.091020130910201389463364017420133172013©The American Society of Tropical Medicine and Hygiene2013This is an Open Access article distributed under the terms of the American Society of Tropical Medicine and Hygiene's Re-use License which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

In 2010, toxigenic Vibrio cholerae was newly introduced to Haiti. Because resources are limited, decision-makers need to understand the effect of different preventive interventions. We built a static model to estimate the potential number of cholera cases averted through improvements in coverage in water, sanitation and hygiene (WASH) (i.e., latrines, point-of-use chlorination, and piped water), oral cholera vaccine (OCV), or a combination of both. We allowed indirect effects and non-linear relationships between effect and population coverage. Because there are limited incidence data for endemic cholera in Haiti, we estimated the incidence of cholera over 20 years in Haiti by using data from Malawi. Over the next two decades, scalable WASH interventions could avert 57,949–78,567 cholera cases, OCV could avert 38,569–77,636 cases, and interventions that combined WASH and OCV could avert 71,586–88,974 cases. Rate of implementation is the most influential variable, and combined approaches maximized the effect.

Disclaimer: The findings and conclusions expressed in this report do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Introduction

In October 2010, cholera was introduced to earthquake-stricken Haiti.1 Within days of its introduction, a National Cholera Surveillance System was implemented.1 Through June 30, 2013, Haiti had reported 663,134 cases of cholera (Figure 1)2; of these, 366,995 (55.3%) were hospitalized and 8160 (1.2%) died. As we approach the three-year mark, cholera will likely be considered endemic to Haiti.

Total (n = 663,134) cholera cases by week, Haiti, October 20, 2010–June 30, 2013.

Water, sanitation, and hygiene (WASH) interventions, such as latrines, point-of-use chlorination and piped water, have long been recognized as effective prevention measures against cholera and other diarrheal diseases.312 In 2008, 63% of the Haitian population had access to improved water and 17% to improved sanitation.13 In 2010, after the earthquake, the Haitian Directorate for Potable Water and Sanitation reported that 26% of the rural population received improved water and 10% improved sanitation; in the Port-au-Prince metropolitan area, the coverage was 35% and 20%, respectively (Haitian Directorate for Potable Water and Sanitation five-year plan). Many public health scientists believe that sustained improvements in access to safe water and sanitation can eliminate transmission of cholera in Haiti, citing interventions used throughout South and Central America in the 1990s.14,15 The WASH interventions, including hand washing, have the additional benefit of reducing the incidence of other diarrheal and respiratory diseases.3,5,16,17 Although improving water and sanitation infrastructure is the ultimate goal of the Haitian Government and the international community, it will take considerable time.18

Oral cholera vaccine (OCV) has been proposed as an effective adjunct for cholera control in endemic and epidemic settings.19,20 Two whole-cell, killed, World Health Organization–prequalified OCVs are available: Dukoral® (Crucell, Stockholm, Sweden) and Shanchol™ (Shantha Biotechnics, Hyderabad, India). Both vaccines require two doses given two weeks apart, with protective immunity developing approximately one week after the second dose.21,22 The Haitian government sanctioned two pilot studies23 to assess the acceptability and feasibility of Shanchol™ vaccine, one in urban Haiti and one in rural Haiti.24 Based on these pilot study findings and findings from previous OCV studies, the Pan American Health Organization has recommended targeted or mass OCV campaigns that use Shanchol™ as an intermediate bridge to reduce cholera transmission in Haiti while improvements in water and sanitation infrastructure are implemented.24 We present results of a model that illustrates the potential impact of WASH and OCV interventions independently and in combination. These results can aid public health decision makers in allocating resources to prevent cholera transmission in Haiti.

Methods

We used Excel 2010 (Microsoft, Redmond, WA) to develop a spreadsheet-based, static mathematical model in which we allowed a degree of indirect protection (or herd immunity) for OCV and WASH interventions by including non-linear relationships between percentage of population covered and percentage of population effectively protected (i.e., for a given percentage vaccinated or who received WASH interventions, an additional percentage was also indirectly protected). For WASH interventions, we included latrines, point-of-use chlorination, and community piped water (standpipes). We divided Haiti's population into urban and rural elements. For both urban and rural populations, and for each intervention, we constructed three scenarios that illustrated potential rates-of-growth of coverage over 20 years. We also constructed scenarios in which we allowed a combination of WASH and OCV in rural and urban areas. In these combined scenarios, we conservatively assumed that persons who received OCV would not be covered by WASH interventions and vice versa. Thus, coverage for either WASH or for OCV interventions would never exceed 50%. We modeled 16 scenarios: six WASH, six OCV, and four that combined WASH and OCV interventions. For further details, see Online Supplemental Materials.

Demographics and expected annual incidence.

We used current population figures for Haiti stratified by rural and urban environments, and estimated population growth rate to project demographic growth over a 20-year period (Supplemental Table 1). Because toxigenic Vibrio cholerae was only recently introduced in Haiti, and cholera incidence has changed from an epidemic to an endemic pattern (Figure 1),2 there are no data describing the incidence of endemic cholera in Haiti over a 20-year period. Therefore, we estimated the 20-year annual incidence of endemic cholera in Haiti by using 1990–2010 annual incidence data from Malawi as reported to the World Health Organization.25 We chose Malawi because it faces similar socioeconomic challenges to those seen in Haiti (e.g., poor roads, relatively high infant mortality rate, large population without piped water, rates of literacy < 80%).26 We also performed sensitivity analyses by using annual incidence data for endemic cholera from Mozambique and India, as well as a set of hypothetical annual incidence data (Online Supplemental Material).

Intervention effectiveness.

For each intervention, we included non-linear relationships between coverage and effectiveness that take into account indirect protective effects27 (Figure 2). For OCV (Shanchol™), we fitted an exponential curve to the OCV (Dukarol®) coverage-effectiveness modeling data from Longini and others.28 (Figure 2; Supplemental Table 2). The randomized control trial data for Shanchol™ administered as a two-dose regimen showed a direct efficacy of 67% after two years, which is nearly identical to that for Dukarol®21 and 66% after three years.29,30 Therefore, we assumed that our use of the Dukarol® coverage-effectiveness curve as a proxy for the Shanchol™ coverage-effectiveness curve was reasonable. We did not examine partial vaccination effect (i.e., receiving only one dose). The OCV coverage in our model implies effective coverage with two doses of Shanchol™ vaccine, and in addition, assumes that all two dose recipients will receive one booster dose every three years thereafter (Supplemental Table 4). For latrines and point-of-use chlorination, we estimated non-linear curves based on data from two reviews of interventions3,5 (Figure 2; Supplemental Table 2). For piped water, we assumed a non-linear curve with a protective effect of 90% at 100% coverage (Figure 2; Supplemental Table 2). Because there are little data on the synergistic effect of one or more WASH interventions, we used a conservative approach and assumed no additive effect across the various combinations of possible WASH interventions.7 Therefore, we used a stepwise introduction of WASH interventions over time, and the intervention with the stronger protective effect supplanted the other (i.e., piped water > chlorinated water > latrines). For further detail, see the Online Supplemental Material.

Coverage-effectiveness curves for various interventions. Black line indicates oral cholera vaccine; dark gray dotted line indicates piped water; gray dotted-dashed line indicates point-of-use chlorination; light gray dashed line indicates latrines.

Intervention coverage over time.

For each urban (U) and rural (R) population, we modeled three rates of intervention implementation over 20 years for WASH (WASH/U 1, U 2, U 3 and WASH/R 1, R 2, R 3) and OCV (OCV/U 1, U 2, U 3 and OCV/R 1, R 2, R 3) interventions (Tables 1 and 2; Supplemental Figures 1, 3, and 4). We assumed that five persons shared one latrine and 50 persons shared one community piped water standpipe. Point-of use chlorination was assumed to occur at a household level. We also assumed that in the first five years of implementation, WASH resources would primarily be allocated towards point-of-use chlorination and that piped water would begin in year 6.

In addition, we generated two scenarios that combined WASH and OCV for each of the urban and rural settings (Table 3) . The four combined scenarios differ in coverage rate achieved by year 20 for each WASH and OCV intervention. For example, in the first urban and rural combined scenarios (Combined/U1, Combined/R1), we assumed that OCV reached peak coverage of 20% at year 5 and then decreased to 5% by year 20. For the second urban and rural combined scenarios (Combined/U2, Combined/R2), we assumed that OCV coverage peaked at 10% in year 5 and then decreased to 0% by year 20.

Number of cholera cases averted.

Using endemic cholera incidence data from Malawi, we calculated potential cases averted for each scenario by multiplying the estimated incidence and the protective effect of the intervention(s). Cumulative cases averted were discounted by 3% per year.31

Uncertainty/sensitivity analyses.

To assess the robust nature of our model, we performed uncertainty/sensitivity analyses in three steps. First, we varied the baseline incidence rates to see if the change in input would change our results. We used endemic cholera incidence data from Mozambique (1990–2010) and India (1961–1981) to model countries with a higher and a lower mean incidence, respectively. We also created hypothetical scenarios with stable, growing, and decreasing cholera incidence to determine whether different secular trends in annual incidence would change our results. Second, we varied the coverage-effectiveness curves for latrines, point-of-use chlorination, and community piped water to enable uncertainty of the estimates of the protective effectiveness of these WASH interventions. The ranges for their protective effectiveness at 100% intervention coverage are latrines (95% confidence interval = 8–46%), point-of-use chlorination (95% CI = 32–83%), and piped water 90% (default value), and 100% (complete protection) (Supplemental Figure 2). Third, we varied the implementation rate of WASH, OCV, or a combination of both interventions to determine how the number of cumulative cholera cases averted would vary.

OCV uncertainty/sensitivity analyses.

We varied OCV coverage at year 20 from 1% to 100%. We assumed that effective OCV coverage increased linearly for 20 years.

WASH uncertainty/sensitivity analyses.

For latrines, we assumed that in urban Haiti, the percentage of persons with access to latrines only remained the same for the first five years and then was gradually replaced by point-of-use chlorination or piped water; in rural Haiti, the latrine coverage increased at a constant rate from 10% at year 0 to 30% at year 5 and continues to increase at the same rate thereafter until it is gradually replaced by point-of-use chlorination or piped water. Point-of-use chlorination coverage remained at baseline (20% in urban areas and 26% in rural areas) through year 20, or increased to various levels by year 5 (30%, 50%, 70%, or 90% in urban and rural areas, respectively), increasing thereafter through year 20 in the absence of piped water. Piped water coverage remained at baseline (10% in urban areas and 0% in rural areas) for the first five years, increasing thereafter through year 20.

Combined WASH and OCV uncertainty/sensitivity analyses.

In our combined scenarios, we assumed that the respective coverage of OCV and WASH does not exceed 50%. Those persons who would receive OCV would not receive any WASH interventions and vice versa. We assumed that latrine only coverage remained at the baseline (10%) until those persons also received point-of-use chlorination or piped water interventions. Point-of-use chlorination coverage increased from baseline (20% for urban areas and 26% for rural areas) to 30% at year 5, and continued to increase at a constant rate until piped water replaced it (sensitivity analysis scenario 1); or its coverage remained unchanged at the baseline from year 0 to year 5 and remained unchanged for subsequent years until piped water replaced it (sensitivity analysis scenario 2). Piped water coverage remained at baseline (10% in urban areas and 0% in rural areas) for the first 5 years, and increased at a constant rate thereafter to reach 10%, 20%, 30%, 40%, or 50%, respectively, by year 20. The OCV coverage increased at a constant rate from 1% (baseline) at year 0, peaked at year 5, and decreased thereafter at a constant rate to reach 5% at year 20. We varied the OCV coverage attained at year 5 from 1% (baseline) to 50%. Finally, we ran two sets of sensitivity analyses of the four combined interventions in which we first assumed that OCV coverage increased at a constant rate from 1% baseline at year 0 and reached 50% at year 5, and then either decreased at a constant rate to 5% at year 20 or remained at 50% through year 20 (i.e., no decrease) (see Online Supplemental Material).

Results

We developed eight urban scenarios (three WASH, three OCV, and two WASH/OCV combined) and eight rural scenarios (three WASH, three OCV, and two WASH/OCV combined). WASH scenario 1 (WASH/R1 + WASH/U1) averted 78,567 cases of cholera. WASH scenario 2 (WASH/R2 + WASH/U2) averted 71,106 cases of cholera. WASH scenario 3 (WASH/R3 + WASH/U3) averted 57,949 cases of cholera (Tables 1 and 4, Figure 3).

Cumulative cases of cholera averted by water, sanitation and hygiene (WASH) interventions, oral cholera vaccine interventions (OCV) or a combination of both (Combi) over a 20-year period in Haiti, and assuming a baseline national cholera incidence rate from Malawi (1990–2010) applied to urban and rural Haiti.

OCV scenario 1 (OCV/R1 + OCV/U1) averted 77,636 cases of cholera. OCV scenario 2 (OCV/R2 + OCV/U2) averted 57,668 cases of cholera. OCV scenario 3 (OCV/R3 + OCV/U3) averted 38,569 cases of cholera (Tables 2 and 4, Figure 3).

The rate of intervention coverage extension had the largest effect on cases of cholera averted (the difference between scenarios 1, 2 and 3 for either WASH or OCV).

Combined scenario 1 (Combined/R1 + Combined/U1) averted 88,974 cholera cases. Combined scenario 2 (Combined/R2 + Combined/U2) averted 71,586 cholera cases (Tables 3 and 4, Figure 3).

In our sensitivity analyses, we found that although the absolute number of cases of cholera averted is sensitive to the expected number of cholera cases given different baseline annual incidence of cholera, the relative effect of each intervention scenario is the same (Figure 4

Cumulative cases of urban (U) cholera cases averted by water, sanitation and hygiene (WASH/U1), oral cholera vaccine (OCV/U1) and a combination of WASH and OCV (Combined/U 1) scenarios when 20-year baseline annual incidence data from Malawi (1990–2010), Mozambique (1990–2010) and India (1961–1981) are applied to Haiti demographic data.

; Supplemental Figure 1). Our sensitivity analysis of combined interventions (Figure 5

Cumulative cholera cases averted over 20 years in Haiti by combined water, sanitation and hygiene (WASH) and oral cholera vaccine (OCV) intervention scenarios. The x-axis refers to OCV coverage at year 5, and the different lines refer to the proportion of total piped water coverage (10%, 20%, 30%, 40%, and 50%) at year 20. We assumed that 1) persons who received OCV would not be covered by WASH interventions and vice versa; 2) WASH and OCV interventions never exceed 50%, respectively; 3) point-of-use chlorination increases from 20% (urban), or 26% (rural) and will remain the same until piped water takes over (provided assumption 1 met); 4) latrine coverage remains 10% until it is taken over by point-of-use chlorination or piped water; 5) piped water baseline = 0% in rural areas and 10% in urban areas, and piped water coverage starts increasing at a constant rate from year 6 onwards; and 6) OCV coverage increases at a constant rate from 1% baseline at year 0, peaks at year 5 and decreases thereafter at a constant rate to reach 5% at year 20.

) demonstrated decreasing returns on investment (marginal increase of the number of cholera cases averted) when OCV coverage at year 5 and piped water coverage at year 20 are high. The OCV coverage of 30% at year 5 achieved similar outcomes with that of 50% coverage at year 5, regardless of piped water coverage of 10–50% at year 20 (Online Supplemental Material).

In our final sensitivity analysis, we explored scenarios to assess the impact on cases averted after a more rapid scale up of OCV coverage by year 5, as well as scenarios with sustained OCV coverage to year 20 (Table 5) . In our four combined scenarios described in Table 3, OCV coverage reached either 20% or 10% at year 5, and decreased to 5% or 0% by year 20, respectively (Combined/U1, Combined/R1, Combined/U2, Combined/R2). For Combined/U1 + R1, effective OCV coverage increased from 1% at year 0 at a constant rate, reached 20% at year 5, then decreased at a constant rate to 5% at year 20 (Table 3), thereby averting 88,974 cases over 20 years (Table 4). If in this scenario, effective OCV coverage was allowed to reach 50% at year 5, and then decrease at a constant rate to 5% at year 20, an additional 6,738 cases (95,712 cases) would be averted (Table 5). For Combined/U2 + R2, effective OCV coverage increased from 1% at year 0 at a constant rate, reached 10% at year 5, then decreased at a constant rate at 0% at year 20 (Table 3), thereby averting 71,586 cases over 20 years (Table 4). If in this scenario, effective OCV coverage were allowed to reach 50% at year 5, and then decrease at a constant rate to 5% at year 20, an additional 23,933 (95,519 cases) would be averted (Table 5). However, we estimated very small further increases in cases averted when we allowed for effective OCV coverage to reach 50% by year 5 and remain at that level to year 20 (Table 5). For example, in modified scenario Combined/U1 + R1, sustaining 50% coverage from year 5 through year 20 resulted in 95,777 cases averted (i.e., an additional 65 cases averted). Similar modest increases in case averted (95,703 cases averted; i.e., an additional 184 cases averted) were estimated for Combined/U2 + R2 (Table 5). For results of the other sensitivity/uncertainty analyses, see Online Supplemental Material.

Discussion

Our results demonstrate that the rate of expanding coverage of WASH and OCV interventions affects the cumulative number of cases of cholera averted. The scenarios demonstrate that the modeled WASH and OCV interventions averted similar numbers of cholera cases. The assumptions of coverage for this model took into consideration the theoretical implementation of WASH and OCV interventions. Our goal was to demonstrate the scope of results given different rates of implementation and levels of coverage attained through a variety of scenarios, as well as with the sensitivity and uncertainty analyses. Scenarios that combined WASH and OCV interventions were most effective, which supports current efforts to implement both interventions when feasible.24

The WASH infrastructure provides a long-term, sustainable solution for prevention of cholera.12 Evidence from Europe and North America over the past two centuries, and more recently from Latin America, demonstrate that as water and sanitation coverage improves, the risk of epidemic or endemic cholera transmission is greatly reduced.12,14,15 WASH also prevents the transmission of many other diarrheal diseases, which in Haiti, as in many developing countries, is a leading killer of children less than five years of age.32,33 The overall benefit of expanding WASH coverage extends far beyond its effect on cholera alone.

The OCVs should help reduce the burden of cholera while WASH coverage is expanded, given the considerable amount of time required to improve WASH infrastructure (e.g., piped water and sewers). However, an OCV program should not be considered as a long-term alternative substitute for WASH. Implementation of OCVs will present its own challenges. Currently available OCVs are not 100% efficacious, induced immunity wanes over time thereby requiring periodic booster dosing, and today's globally available OCV supply is not sufficient to vaccinate the entire Haitian population with the required two-dose regimen. In addition, evidence from the routine childhood expanded program for immunizations and recent nationwide vaccine campaigns in Haiti has demonstrated varying ranges of coverage.3437 Although rapid expansion of effective OCV coverage to 50% of Haitian population (10 million doses of administered vaccine or more) by year 5 may avert an additional 6,000–24,000 cases (Table 5), such rapid expansion is likely beyond the country's current capacity. Therefore, we highlight coverage scenarios (Table 3) in our model that we believe could be realistically achieved based on Haiti's recent experience with routine expanded program for immunizations and vaccine campaigns.

Our study has several limitations. First, we chose a static model while simultaneously incorporating an indirect effect by applying non-linear coverage-effective curves to WASH and OCV interventions. Thus, the model takes into account the current effect of an intervention (direct and indirect protection) and is an improvement over a classical static model. Unlike a model that simulates the transmission dynamics of cholera over time (e.g., ordinary differential equation models),38 a static model does not account for the future effect of the current intervention because the baseline incidence does not take into account the intervention applied in the previous year(s). However, our static model, like others,39,40 avoids having to estimate uncertain and unknown parameters required for dynamic models that explore the impact of multiple interventions introduced at various stages over time.41 More data will be needed to reduce the parameter uncertainty of existing dynamic models of cholera for Haiti.41,42 Second, although we accounted for population growth, we did not account for the likely migration of the Haitian population from rural to urban areas over the next 20 years. Third, we recognize that the baseline 20-year annual cholera incidence data from Malawi, Mozambique, and India that we used as illustrations for medium, high, and low incidence, respectively, may have been subject to under-reporting. However, our findings were robust across all three baseline country scenarios. However, it is clear that every country's experience with endemic cholera is unique. Only time will tell what Haiti's experience will be. Fourth, apart from modeling urban and rural Haiti separately, we did not study the impact of geographic variation on cholera incidence and intervention implementation (e.g., targeted immunization). Fifth, we acknowledge the uncertainty associated with the coverage-effectiveness curve used for each intervention. However, because data are sparse for OCV and WASH intervention coverage-effectiveness curves, we used modeling outputs of Longini and others28 to fit our exponential curves for OCV, and we also applied exponential curves to the WASH coverage-effectiveness relationship.27

Our study emphasizes that intervention coverage affects variation in estimated number of cumulative cholera cases averted over an extended period, and demonstrates the probable synergistic effects of WASH and OCV when used in combination. Our study should not be interpreted as an exact prediction for the number of cholera cases that could be averted in Haiti under the scenarios outlined, but it serves to demonstrate that WASH and OCV interventions can play an important role in decreasing the burden of cholera, and that maximizing intervention coverage is the central variable to their success. Transmission and intervention dynamics need to be understood so that informed decisions can be made about how to allocate limited resources. The Haitian Government recently released its National Plan for the Elimination of Cholera.18 This plan outlines a combination of public health interventions that include the use of OCV while expanding access to clean water and sanitation. Our study suggests that this combined strategy will be effective.

Supplementary Material

Supplemental Datas.

ACKNOWLEDGMENTS

We thank Manoj Gambhir, Richard Gelting, Tom Handzel, Eric Mintz, Daphne Moffett, Scott Santibanez, and Cathy Young for their valuable comments on earlier versions of this manuscript, and Cathy Young for editorial assistance.

Authors' addresses: Isaac Chun-Hai Fung, Rebekah H. Borse, and Martin I. Meltzer, Health Economics and Modeling Unit, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, E-mails: cfung@georgiasouthern.edu, rebekahheinzen@gmail.com, and qzm4@cdc.gov. David L. Fitter and Jordan W. Tappero, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, E-mails: vid3@cdc.gov and jwt0@cdc.gov.

BarzilayEJSchaadNMagloireRMungKSBoncyJDahourouGAMintzEDSteenlandMWVertefeuilleJFTapperoJW 2013 Cholera surveillance during the Haiti epidemic–the first 2 years N Engl J Med 368 599 60923301694 Ministère de Santé Publique et de la Population 2013 Rapports Journaliers du MSPP sur l'Évolution du Cholera en Haiti Available athttp://www.mspp.gouv.ht/site/downloads/Rapport%20journalier%20MSPP%20du%2030%20juin%202013.pdf Accessed July 26, 2013 ClasenTRobertsIRabieTSchmidtWCairncrossS 2006 Interventions to improve water quality for preventing diarrhoea Cochrane Database Syst Rev 3 CD00479416856059 ClasenTSchmidtWPRabieTRobertsICairncrossS 2007 Interventions to improve water quality for preventing diarrhoea: systematic review and meta-analysis BMJ 334 78217353208 ClasenTFBostoenKSchmidtWPBoissonSFungICJenkinsMWScottBSugdenSCairncrossS 2010 Interventions to improve disposal of human excreta for preventing diarrhoea Cochrane Database Syst Rev CD00718020556776 WaddingtonHSnilstveitB 2009 Effectiveness and sustainability of water, sanitation, and hygiene interventions in combating diarrhoea J Development Effectiveness 1 295 335 FewtrellLKaufmannRBKayDEnanoriaWHallerLColfordJMJr 2005 Water, sanitation, and hygiene interventions to reduce diarrhoea in less developed countries: a systematic review and meta-analysis Lancet Infect Dis 5 42 5215620560 CairncrossSHuntCBoissonSBostoenKCurtisVFungICSchmidtWP 2010 Water, sanitation and hygiene for the prevention of diarrhoea Int J Epidemiol 39 (Suppl 1) i193 i20520348121 ArnoldBFColfordJMJr 2007 Treating water with chlorine at point-of-use to improve water quality and reduce child diarrhea in developing countries: a systematic review and meta-analysis Am J Trop Med Hyg 76 354 36417297049 SnowJ 1855 On the Mode of Communication of Cholera London, England John Churchill SnowJ 1854 On the communication of cholera by impure Thames water Medical Times and Gazette 9 365 366 WaldmanRJMintzEDPapowitzHE 2013 The cure for cholera: improving access to safe water and sanitation N Engl J Med 368 592 59423301693 WHO/UNICEF Joint Monitoring Programme for Water Supply and Sanitation 2010 Progress on Sanitation and Drinking-Water: 2010 Update Geneva World Health Organization SepulvedaJValdespinoJLGarcia-GarciaL 2006 Cholera in Mexico: the paradoxical benefits of the last pandemic Int J Infect Dis 10 4 1316326125 Roses PeriagoMFriedenTRTapperoJWDe CockKMAasenBAndrusJK 2012 Elimination of cholera transmission in Haiti and the Dominican Republic Lancet 379 e12 e1322240408 CairncrossS 2003 Handwashing with soap: a new way to prevent ARIs? Trop Med Int Health 8 677 67912869087 SchmidtWPCairncrossSBarretoMLClasenTGenserB 2009 Recent diarrhoeal illness and risk of lower respiratory infections in children under the age of 5 years Int J Epidemiol 38 766 77219279073 Direction Nationale de L'Eau Potable et de L'Assainissement (Ministry of Public Health and Population of the Republic of Haiti) 2013 National Plan for the Elimination of Cholera in Haiti 2013–2022 (English Translation) Available athttp://new.paho.org/hq/index.php?option=com_docman&task=doc_download&gid=20326&Itemid=270&lang=en Accessed March 23, 2013 IversLCFarmerPAlmazorCPLeandreF 2010 Five complementary interventions to slow cholera: Haiti Lancet 376 2048 205121146206 World Health Organization 2010 Cholera vaccines: WHO position paper Wkly Epidemiol Rec 85 117 12820349546 DateKAVicariAHydeTBMintzEDanovaro-HollidayMCHenryATapperoJWRoelsTHAbramsJBurkholderBTRuiz-MatusCAndrusJDietzV 2011 Considerations for oral cholera vaccine use during outbreak after earthquake in Haiti, 2010–2011 Emerg Infect Dis 17 2105 211222099114 ShinSDesaiSNSahBKClemensJD 2011 Oral vaccines against cholera Clin Infect Dis 52 1343 134921498389 IversLCFarmerPEPapeWJ 2012 Oral cholera vaccine and integrated cholera control in Haiti Lancet 379 2026 202822656874 Pan American Health Organization 2012 Final Report of the XX Technical Advisory Group (TAG) Meeting on Vaccine-Preventable Diseases Pan American Health Organization Washington, DC October 2012 World Health Organization 2013 Global Health Observatory. Number of Reported Cholera Cases Available athttp://www.who.int/gho/epidemic_diseases/cholera/cases/en/index.html Accessed October 2, 2012 Central Intelligence Agency 2013 The World Factbook. Malawi Available athttps://www.cia.gov/library/publications/the-world-factbook/geos/mi.html Accessed March 22, 2013 FungIC-HFitterDLMeltzerMITapperoJWBorseRH 2013 Coverage-effectiveness curve: evaluating the impact of water, sanitation and hygiene interventions CDC/NCEZID/Division of Preparedness and Emerging Infections, white paper, Atlanta LonginiIMJrNizamAAliMYunusMShenviNClemensJD 2007 Controlling endemic cholera with oral vaccines PLoS Med 4 e33618044983 SurDKanungoSSahBMannaBAliMPaisleyAMNiyogiSKParkJKSarkarBPuriMKKimDRDeenJLHolmgrenJCarbisRRaoRNguyenTVHanSHAttridgeSDonnerAGangulyNKBhattacharyaSKNairGBClemensJDLopezAL 2011 Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial PLoS Negl Trop Dis 5 e128922028938 SurDLopezALKanungoSPaisleyAMannaBAliMNiyogiSKParkJKSarkarBPuriMKKimDRDeenJLHolmgrenJCarbisRRaoRNguyenTVDonnerAGangulyNKNairGBBhattacharyaSKClemensJD 2009 Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial Lancet 374 1694 170219819004 CorsoPSHaddixAC 2003 Time Effects. Prevention Effectiveness: A Guide to Decision Analysis and Economic Evaluation New York Oxford University Press MurrayCJVosTLozanoRNaghaviMFlaxmanADMichaudCEzzatiMShibuyaKSalomonJAAbdallaSAboyansVAbrahamJAckermanIAggarwalRAhnSYAliMKAlvaradoMAndersonHRAndersonLMAndrewsKGAtkinsonCBaddourLMBahalimANBarker-ColloSBarreroLHBartelsDHBasanezMGBaxterABellMLBenjaminEJBennettDBernabeEBhallaKBhandariBBikbovBBin AbdulhakABirbeckGBlackJABlencoweHBloreJDBlythFBolligerIBonaventureABoufousSBourneRBoussinesqMBraithwaiteTBrayneCBridgettLBrookerSBrooksPBrughaTSBryan-HancockCBucelloCBuchbinderRBuckleGBudkeCMBurchMBurneyPBursteinRCalabriaBCampbellBCanterCECarabinHCarapetisJCarmonaLCellaCCharlsonFChenHChengATChouDChughSSCoffengLEColanSDColquhounSColsonKECondonJConnorMDCooperLTCorriereMCortinovisMde VaccaroKCCouserWCowieBCCriquiMHCrossMDabhadkarKCDahiyaMDahodwalaNDamsere-DerryJDanaeiGDavisADe LeoDDegenhardtLDellavalleRDelossantosADenenbergJDerrettSDes JarlaisDCDharmaratneSDDheraniMDiaz-TorneCDolkHDorseyERDriscollTDuberHEbelBEdmondKElbazAAliSEErskineHErwinPJEspindolaPEwoigbokhanSEFarzadfarFFeiginVFelsonDTFerrariAFerriCPFèvreEMFinucaneMMFlaxmanSFloodLForemanKForouzanfarMHFowkesFGFransenMFreemanMKGabbeBJGabrielSEGakidouEGanatraHAGarciaBGaspariFGillumRFGmelGGonzalez-MedinaDGosselinRGraingerRGrantBGroegerJGuilleminFGunnellDGuptaRHaagsmaJHaganHHalasaYAHallWHaringDHaroJMHarrisonJEHavmoellerRHayRJHigashiHHillCHoenBHoffmanHHotezPJHoyDHuangJJIbeanusiSEJacobsenKHJamesSLJarvisDJasrasariaRJayaramanSJohnsNJonasJBKarthikeyanGKassebaumNKawakamiNKerenAKhooJPKingCHKnowltonLMKobusingyeOKorantengAKrishnamurthiRLadenFLallooRLaslettLLLathleanTLeasherJLLeeYYLeighJLevinsonDLimSSLimbELinJKLipnickMLipshultzSELiuWLoaneMOhnoSLLyonsRMabweijanoJMacIntyreMFMalekzadehRMallingerLManivannanSMarcenesWMarchLMargolisDJMarksGBMarksRMatsumoriAMatzopoulosRMayosiBMMcAnultyJHMcDermottMMMcGillNMcGrathJMedina-MoraMEMeltzerMMensahGAMerrimanTRMeyerACMiglioliVMillerMMillerTRMitchellPBMockCMocumbiAOMoffittTEMokdadAAMonastaLMonticoMMoradi-LakehMMoranAMorawskaLMoriRMurdochMEMwanikiMKNaidooKNairMNNaldiLNarayanKMNelsonPKNelsonRGNevittMCNewtonCRNolteSNormanPNormanRO'ConnellMO'HanlonSOlivesCOmerSBOrtbladKOsborneROzgedizDPageAPahariBPandianJDRiveroAPPattenSBPearceNPadillaRPPerez-RuizFPericoNPesudovsKPhillipsDPhillipsMRPierceKPionSPolanczykGVPolinderSPopeCA IIIPopovaSPorriniEPourmalekFPrinceMPullanRLRamaiahKDRanganathanDRazaviHReganMRehmJTReinDBRemuzziGRichardsonKRivaraFPRobertsTRobinsonCDe LeònFRRonfaniLRoomRRosenfeldLCRushtonLSaccoRLSahaSSampsonUSanchez-RieraLSanmanESchwebelDCScottJGSegui-GomezMShahrazSShepardDSShinHShivakotiRSinghDSinghGMSinghJASingletonJSleetDASliwaKSmithESmithJLStapelbergNJSteerASteinerTStolkWAStovnerLJSudfeldCSyedSTamburliniGTavakkoliMTaylorHRTaylorJATaylorWJThomasBThomsonWMThurstonGDTleyjehIMTonelliMTowbinJATruelsenTTsilimbarisMKUbedaCUndurragaEAvan der WerfMJvan OsJVavilalaMSVenketasubramanianNWangMWangWWattKWeatherallDJWeinstockMAWeintraubRWeisskopfMGWeissmanMMWhiteRAWhitefordHWiebeNWiersmaSTWilkinsonJDWilliamsHCWilliamsSRWittEWolfeFWoolfADWulfSYehPHZaidiAKZhengZJZoniesDLopezADAlMazroaMAMemishZA 2012 Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 Lancet 380 2197 222323245608 LozanoRNaghaviMForemanKLimSShibuyaKAboyansVAbrahamJAdairTAggarwalRAhnSYAlvaradoMAndersonHRAndersonLMAndrewsKGAtkinsonCBaddourLMBarker-ColloSBartelsDHBellMLBenjaminEJBennettDBhallaKBikbovBBin AbdulhakABirbeckGBlythFBolligerIBoufousSBucelloCBurchMBurneyPCarapetisJChenHChouDChughSSCoffengLEColanSDColquhounSColsonKECondonJConnorMDCooperLTCorriereMCortinovisMde VaccaroKCCouserWCowieBCCriquiMHCrossMDabhadkarKCDahodwalaNDe LeoDDegenhardtLDelossantosADenenbergJDes JarlaisDCDharmaratneSDDorseyERDriscollTDuberHEbelBErwinPJEspindolaPEzzatiMFeiginVFlaxmanADForouzanfarMHFowkesFGFranklinRFransenMFreemanMKGabrielSEGakidouEGaspariFGillumRFGonzalez-MedinaDHalasaYAHaringDHarrisonJEHavmoellerRHayRJHoenBHotezPJHoyDJacobsenKHJamesSLJasrasariaRJayaramanSJohnsNKarthikeyanGKassebaumNKerenAKhooJPKnowltonLMKobusingyeOKorantengAKrishnamurthiRLipnickMLipshultzSEOhnoSLMabweijanoJMacIntyreMFMallingerLMarchLMarksGBMarksRMatsumoriAMatzopoulosRMayosiBMMcAnultyJHMcDermottMMMcGrathJMensahGAMerrimanTRMichaudCMillerMMillerTRMockCMocumbiAOMokdadAAMoranAMulhollandKNairMNNaldiLNarayanKMNasseriKNormanPO'DonnellMOmerSBOrtbladKOsborneROzgedizDPahariBPandianJDRiveroAPPadillaRPPerez-RuizFPericoNPhillipsDPierceKPopeCA IIIPorriniEPourmalekFRajuMRanganathanDRehmJTReinDBRemuzziGRivaraFPRobertsTDe LeónFRRosenfeldLCRushtonLSaccoRLSalomonJASampsonUSanmanESchwebelDCSegui-GomezMShepardDSSinghDSingletonJSliwaKSmithESteerATaylorJAThomasBTleyjehIMTowbinJATruelsenTUndurragaEAVenketasubramanianNVijayakumarLVosTWagnerGRWangMWangWWattKWeinstockMAWeintraubRWilkinsonJDWoolfADWulfSYehPHYipPZabetianAZhengZJLopezADMurrayCJAlMazroaMAMemishZA 2012 Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 Lancet 380 2095 212823245604 RaineyJJDanovaro-HollidayMCMagloireRKanandaGLeeCEChamouilletHLacapereFMungKLumanET 2011 Haiti 2007–2008 national measles-rubella vaccination campaign: implications for rubella elimination J Infect Dis 204 (Suppl 2) S616 S62121954256 RaineyJJLacapereFDanovaro-HollidayMCMungKMagloireRKanandaGCadetJRLeeCEChamouilletHLumanET 2012 Vaccination coverage in Haiti: results from the 2009 national survey Vaccine 30 1746 175122227146 LacapereFMagloireRDanovaro-HollidayMCFlanneryBChamoullietHCelestinEP 2011 The use of rapid coverage monitoring in the national rubella vaccination campaign, Haiti 2007–2008 J Infect Dis 204 (Suppl 2) S698 S70521954269 VertefeuilleJFDowellSFDomercantJWTapperoJW 2013 Cautious optimism on public health in post-earthquake Haiti Lancet 381 517 51923332167 ChaoDLLonginiIMJrMorrisJGJr 2013 Modeling cholera outbreaks Curr Top Microbiol Immunol [Epub ahead of print] CookJJeulandMMaskeryBLauriaDSurDClemensJWhittingtonD 2009 Using private demand studies to calculate socially optimal vaccine subsidies in developing countries J Policy Anal Manage 28 6 2819090047 ReyburnRDeenJLGraisRFBhattacharyaSKSurDLopezALJiddawiMSClemensJDvon SeidleinL 2011 The case for reactive mass oral cholera vaccinations PLoS Negl Trop Dis 5 e95221283614 GradYHMillerJCLipsitchM 2012 Cholera modeling: challenges to quantitative analysis and predicting the impact of interventions Epidemiology 23 523 53022659546 FungIC-H 2013 Cholera transmission dynamic models for public health practitioners CDC/NCEZID/Division of Preparedness and Emerging Infections, white paper, Atlanta

Water, sanitation, and hygiene (WASH) scenarios with percentage of urban (U) and rural (R) Haitian population covered at years 0, 5, and 20*

ScenarioInterventionYear 0 (%)Year 5 (%)Year 20 (%)
WASH/U1Latrines10100
Point-of-use chlorination + L208025
Piped water + C + L101075
Total40100100
WASH/U2Latrines10100
Point-of-use chlorination + L206050
Piped water + C + L101050
Total4080100
WASH/U3Latrines10100
Point-of-use chlorination + L204080
Piped water + C + L101020
Total4060100
WASH/R1Latrines10300
Point-of-use chlorination + L264030
Piped water + C + L0070
Total3670100
WASH/R2Latrines10208
Point-of-use chlorination + L263042
Piped water + C + L0050
Total3650100
WASH/R3Latrines101010
Point-of-use chlorination + L263042
Piped water + C + L0025
Total364077

C = point-of-use chlorination; L = latrines.

Oral cholera vaccine (OCV) scenarios with percentage of Haitian urban (U) and rural (R) population covered at years 0, 5, and 20

ScenariosYear 0 (%)Year 5 (%)Year 20 (%)
OCV/U115090
OCV/U212060
OCV/U311025
OCV/R115065
OCV/R212040
OCV/R311025

Combined oral cholera vaccine (OCV) and water, sanitation and hygiene (WASH) scenarios by percentage of Haitian urban (U) and rural (R) population covered, and at years 0, 5, and 20*

ScenariosInterventionsYear 0 (%)Year 5 (%)Year 20 (%)
Combined/U1OCV1205
WASH sub-total405050
Latrines10100
Point-of-use chlorination + L20300
Piped water + C + L101050
Combined/U2OCV1100
WASH sub-total405050
Latrines10100
Point-of-use chlorination + L203025
Piped water + C + L101025
Combined/R1OCV1205
WASH sub-total364050
Latrines10100
Point-of-use chlorination + L26300
Piped water + C + L0050
Combined/R2OCV1100
WASH sub-total364050
Latrines10100
Point-of-use chlorination + L263025
Piped water + C + L0025

C = point-of-use-chlorination; L = latrines.

Comparisons of the cumulative number of cases of cholera averted by oral cholera vaccine (OCV) and water, sanitation and hygiene (WASH) scenarios applied to Haitian urban (U) and rural (R) populations by using Malawi, Mozambique, and India 20-year endemic cholera incidence data as baseline*

Baseline incidence rate as applied to HaitiU/RWASH 1WASH 2WASH 3OCV 1OCV 2OCV 3Combi 1Combi 2
Malawi (1990–2010)U42,82841,07234,79438,79329,70419,09346,21338,913
R35,73930,03423,15538,84327,96419,47642,76132,673
Total78,56771,10657,94977,63657,66838,56988,97471,586
Mozambique (1990–2010)U61,87959,31349,42759,22345,93129,52965,38454,827
R52,54143,86533,45259,22943,08530,12162,70447,076
Total114,420103,17882,879118,45289,01659,650128,088101,903
India (1961–1981)U3,7113,5303,0103,4212,5081,5884,1243,473
R2,9112,4541,9563,4372,3871,6203,7532,856
Total6,6225,9844,9666,8584,8953,2087,8776,329

Combi = combination of WASH and OCV.

Total cumulative cholera incidence (with a discounting rate of 3% per year): Malawi baseline incidence rate scenario: 106,994 cases; Mozambique baseline incidence rate scenario: 142,754 cases; India baseline incidence rate scenario: 9,635 cases.

Cumulative number of cases averted in sensitivity analyses of additional combined scenarios of WASH and OCV in urban (U) and rural (R) Haiti*

AnalysisCombined/U1Combined/U2Combined/R1Combined/R2Combined/U1 + R1Combined/U2 + R2
Main analysis in Table 346,21338,91342,76132,67388,97471,586
50% OCV at year 5 decreasing to 5% at year 2048,337 (+2,124)48,189 (+9,276)47,375 (+4,614)47,330 (+14,657)95,712 (+6,738)95,519 (+23,933)
Sustained 50% OCV from year 5 to 2048,371 (+34)48,298 (+109)47,406 (+31)47,405 (+75)95,777 (+65)95,703 (+184)

Incremental differences are indicated in parentheses.

All other assumptions are the same as the combination scenarios as described in Table 3. WASH = water, sanitation, and hygiene; OCV = oral cholera vaccine.